Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API market
Samsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash.
The acquisition will extend Samsung Biologics' manufacturing scope from proteins and antibodies into peptide active pharmaceutical ingredient production.
The move is intended to broaden the company's service portfolio and strengthen its position in the growing peptide market, which is seeing rising demand for therapeutic and diagnostic uses.
The transaction, disclosed on Monday, is one of the larger biotech-related purchases this year and reflects the company's strategy to diversify its manufacturing capabilities.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Samsung Bio to step into peptides in $1.8B buy for PolyPeptide”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that